Human Limb Regeneration.

Practical usefulness For researchers / students / funders: Excellent for quickly surveying the 2025–2026 state of the art, spotting convergence opportunities (HIF1A modulation + biohybrid robots + multichannel scaffolds + immune engineering), and thinking about translational bottlenecks (GMP manufacturing, long-term nanoparticle safety, immune balance, closed-loop monitoring). For clinicians / patients: Useful only as background education. It is not medical advice, a treatment protocol, or a guarantee of any capability. Current standard of care for limb loss remains prosthetics, targeted muscle reinnervation, osseointegration, and limited regenerative approaches (e.g., certain nerve conduits or bone grafts). For policy / ethics discussions: The dedicated ethics section and emphasis on equitable access, long-term monitoring, and transparency are constructive.